Cantargia
Pre-clinicalCantargia is developing an antibody-based treatment targeting the IL1RAP molecule, which has the potential to be used for treatment of cancer as well as auto-immune and inflammatory diseases.
Founded
2001
Focus
AntibodiesBiologics
About
Cantargia is developing an antibody-based treatment targeting the IL1RAP molecule, which has the potential to be used for treatment of cancer as well as auto-immune and inflammatory diseases.
Company Info
TypePrivate
Founded2001
LocationLund, Sweden
StagePre-clinical
Contact
SIMILAR COMPANIES
Basic Genomics
Pre-clinical · Stockholm
2A Pharma
Phase 1 · Stockholm
Abliva
Pre-clinical · Lund
Affibody
Phase 1 · Solna
Alligator Bioscience
Phase 1 · Lund
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile